(S1 (S (NP (NNP Amgen) (NNP Inc.)) (VP (VBD said) (SBAR (S (NP (PRP$ its) (JJ second-quarter) (NNS earnings)) (VP (VBN increased) (ADVP (RBR more) (IN than)) (ADVP (RB tenfold)) (PP (TO to) (NP (NP (QP ($ $) (CD 3.9) (CD million))) (, ,) (CC or) (NP (NP (CD 22) (NNS cents)) (NP (DT a) (NN share))))) (, ,) (PP (JJ due) (PP (TO to) (NP (NP (VBN increased) (NNS sales)) (PP (IN of) (NP (NP (NP (DT the) (NN company) (POS 's)) (JJ new) (NN antianemia) (NN drug)) (PP (IN for) (NP (NN kidney) (NNS patients)))))))))))) (. .)))

(S1 (S (NP (DT The) (ADJP (NNP Thousand) (NNP Oaks) (, ,) (JJ Calif.-based)) (NN biotechnology) (NN company)) (VP (VBD reported) (NP (NP (DT a) (ADJP (CD 97) (NN %)) (NN increase)) (PP (IN in) (NP (NN revenue))) (PP (TO to) (NP (QP ($ $) (CD 42.5) (CD million))))) (PP (IN for) (NP (NP (DT the) (NN quarter)) (VP (VBN ended) (NP (NNP Sept.) (CD 30)))))) (. .)))

(S1 (S (PP (IN In) (NP (DT the) (JJ year-ago) (NN period))) (, ,) (NP (NNP Amgen)) (VP (VBD reported) (NP (NP (JJ net) (NN income)) (PP (IN of) (NP (NP ($ $) (CD 320,000)) (, ,) (CC or) (NP (NP (CD two) (NNS cents)) (NP (DT a) (NN share))) (, ,))) (PP (IN on) (NP (NP (NN revenue)) (PP (IN of) (NP (QP ($ $) (CD 21.5) (CD million)))))))) (. .)))

(S1 (S (PP (IN For) (NP (DT the) (CD six) (NNS months))) (, ,) (NP (DT the) (NN company)) (VP (VBD reported) (NP (NP (DT a) (ADVP (RBR more) (IN than) (RB sixfold)) (NN increase)) (PP (IN in) (NP (NNS earnings)))) (PP (TO to) (NP (NP (QP ($ $) (CD 4.7) (CD million))) (, ,) (CC or) (NP (NP (CD 26) (NNS cents)) (NP (DT a) (NN share))) (, ,))) (PP (IN from) (NP (NP ($ $) (CD 625,000)) (, ,) (CC or) (NP (NP (CD four) (NNS cents)) (NP (DT a) (NN share)))) (ADVP (NP (DT a) (NN year)) (RB ago)))) (. .)))

(S1 (S (NP (NN Revenue)) (VP (VBD rose) (NP (CD 77) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 72.6) (CD million)))) (, ,) (PP (IN from) (NP (NP (JJ last) (NN year) (POS 's)) (QP ($ $) (CD 41) (CD million))))) (. .)))

